Melanoma Initiative To Fund Research
NEW YORK--The Cancer Research Institute and Cancer Care, Inc. have announced The Melanoma Initiative, a program to support public awareness of melanoma, resources for melanoma patients, and clinical research. The Initiative is funded by an unrestricted educational grant from Schering-Plough Corporation.
NEW YORK--The Cancer Research Institute and Cancer Care, Inc. have announcedThe Melanoma Initiative, a program to support public awareness of melanoma,resources for melanoma patients, and clinical research. The Initiativeis funded by an unrestricted educational grant from Schering-Plough Corporation.
Under the auspices of the Initiative's research component, the CancerResearch Institute will establish a program to support phase I/II clinicaltrials aimed at testing novel immunotherapies for melanoma. Close to $1million in grants will be awarded from 1997 to 1999.
Patient outreach services will include counseling and practical assistance;telephone support groups and educational seminars; a "buddy"program where melanoma patients can talk with other patients; guidanceon medical services; a referral program identifying local community resources;and guidance on how to obtain home care, transportation, child care, andfinancial assistance.
These services will be available through Cancer Care's offices, itsNational Counseling Line, 1-800-813-HOPE, and its Web Site (http://www.cancercareinc.org).The centerpiece of the educational outreach component is the creation offour advertisements for People magazine.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
